Article Text
Abstract
The advent of immune checkpoint inhibitors (ICIs) for cancer therapy has heralded increasing frequency of immune-related adverse events including endocrinopathies, hepatitis, colitis and rarely myocarditis and myasthenia gravis (MG). The heterogeneity in clinical presentations regardless of organ-specific involvement can lead to delayed recognition and management of these events and adverse health outcomes. We describe a case of ICI-induced subclinical focal myocarditis that was recognised and treated in the broader context of MG. It is essential that patients with ICI-induced MG should be screened and monitored for myocarditis, a potentially fatal complication.
- heart failure
- radiology (diagnostics)
- malignant disease and immunosuppression
- skin cancer
- unwanted effects / adverse reactions
Statistics from Altmetric.com
Footnotes
Contributors PJL, SLF, HS-IJ and STV had a joint role in conducting a literature review, drafting and editing of the manuscript. PJL was directly involved in the patients acute care and STV continues to have a role in the patients follow up.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.